Real-world effectiveness of CDK4/6 inhibitors on patients with HR+/HER2– advanced breast cancer in South Korea, focusing on underrepresented patients

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Surveillance E, Program ER. Cancer stat facts: female breast cancer subtypes. 2021. Available from: https://seer.cancer.gov/statfacts/html/breast-subtypes.html
   Google Scholar
• Korean Breast Cancer Society. Breast Cancer Facts & Figures 2022. Seoul: Korean Breast Cancer Society; 2022.
   Google Scholar
• Pernas S, Tolaney SM, Winer EP, et al. CDK4/6 inhibition in breast cancer: current practice and future directions. Ther Adv Med Oncol. 2018;10:1758835918786451. doi: 10.1177/1758835918786451.
   Web of Science ®Google Scholar
• Spring LM, Wander SA, Zangardi M, et al. CDK 4/6 inhibitors in breast cancer: current controversies and future directions. Curr Oncol Rep. 2019;21(3):25. doi: 10.1007/s11912-019-0769-3.
   PubMed Web of Science ®Google Scholar
• Gradishar W, Anderson B, Abraham J, et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18:452–478.
   Google Scholar
• Gennari A, André F, Barrios CH, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–1495. doi: 10.1016/j.annonc.2021.09.019.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Somerfield MR, Barton DL, et al. Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2021;39(35):3959–3977. doi: 10.1200/JCO.21.01392.
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936. doi: 10.1056/NEJMoa1607303.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–3646. doi: 10.1200/JCO.2017.75.6155.
   PubMed Web of Science ®Google Scholar
• Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5(1):5. doi: 10.1038/s41523-018-0097-z.
   PubMed Web of Science ®Google Scholar
• Lin C-H, Yap YS, Lee K-H, et al. Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population. J Natl Cancer Inst. 2019;111(12):1298–1306. doi: 10.1093/jnci/djz090.
   PubMedGoogle Scholar
• Im S-A, Mukai H, Park IH, et al. Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: results from the phase III, randomized PALOMA-2 study. J Glob Oncol. 2019;5:1–19. doi: 10.1200/JGO.18.00173.
   Web of Science ®Google Scholar
• Toi M, Inoue K, Masuda N, et al. Abemaciclib in combination with endocrine therapy for east asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials. Cancer Sci. 2021;112(6):2381–2392. doi: 10.1111/cas.14877.
   PubMed Web of Science ®Google Scholar
• Health Insurance Review & Assessment Service. Disease statistics on C50 (2017-2021). 2023. Available from: http://opendata.hira.or.kr/op/opc/olap3thDsInfo.do
   Google Scholar
• European Medicines Agency. ICH Topic E 7. Studies in support of special populations: geriatrics. 1994.
   Google Scholar
• Jang SC, Kwon SH, Min S, et al. Optimal indicator of death for using real-world cancer patients’ data from the healthcare system. Front Pharmacol. 2022;13:906211. doi: 10.3389/fphar.2022.906211.
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Oza AM, Ho TW, et al. Intermediate clinical endpoints: a bridge between progression‐free survival and overall survival in ovarian cancer trials. Cancer. 2015;121(11):1737–1746. doi: 10.1002/cncr.29082.
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139. doi: 10.1097/01.mlr.0000182534.19832.83.
   PubMed Web of Science ®Google Scholar
• Roffman CE, Buchanan J, Allison GT. Charlson comorbidities index. J Physiother. 2016;62(3):171. doi: 10.1016/j.jphys.2016.05.008.
   PubMed Web of Science ®Google Scholar
• Novick D, Lee SY, Koo DH, et al. Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea. J Drug Assess. 2022;11(1):12–19. doi: 10.1080/21556660.2022.2107834.
   PubMed Web of Science ®Google Scholar
• Schneeweiss A, Ettl J, Lüftner D, et al. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer—Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast. 2020;54:88–95. doi: 10.1016/j.breast.2020.08.011.
   PubMed Web of Science ®Google Scholar
• Knudsen ES, Schultz E, Hamilton D, et al. Real-world experience with CDK4/6 inhibitors for metastatic HR+/HER2− breast cancer at a single cancer center. Oncologist. 2022;27(8):646–654. doi: 10.1093/oncolo/oyac089.
   PubMed Web of Science ®Google Scholar
• DeMichele A, Cristofanilli M, Brufsky A, et al. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res. 2021;23(1):37. doi: 10.1186/s13058-021-01409-8.
   PubMed Web of Science ®Google Scholar
• Amaro CP, Batra A, Lupichuk S. First-line treatment with a cyclin-dependent kinase 4/6 inhibitor plus an aromatase inhibitor for metastatic breast cancer in Alberta. Curr Oncol. 2021;28(3):2270–2280. doi: 10.3390/curroncol28030209.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Brufsky A, Liu X, et al. Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer. NPJ Breast Cancer. 2022;8(1):114. doi: 10.1038/s41523-022-00479-x.
   PubMed Web of Science ®Google Scholar
• Brufsky A, Liu X, Li B, et al. Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older. Front Oncol. 2023;13:1237751. doi: 10.3389/fonc.2023.1237751.
   PubMedGoogle Scholar
• Bland JM, Altman DG. Survival probabilities (the Kaplan-Meier method). BMJ. 1998;317(7172):1572–1580. doi: 10.1136/bmj.317.7172.1572.
   PubMed Web of Science ®Google Scholar
• KOSIS. Complete life table (by 1 years). 2022. Available from: https://kosis.kr/statHtml/statHtml.do?orgId=101&tblId=DT_1B42&conn_path=I2
   Google Scholar
• Goyal RK, Holmes HM, Chen H, et al. Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2– metastatic breast cancer in the United States. Breast Cancer Res Treat. 2023;198(1):159–166. doi: 10.1007/s10549-022-06845-4.
   PubMed Web of Science ®Google Scholar
• Senkus E, Łacko A. Over-treatment in metastatic breast cancer. Breast. 2017;31:309–317. doi: 10.1016/j.breast.2016.06.024.
   PubMed Web of Science ®Google Scholar
• Gupta S, Zhang J, Jerusalem G. The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2− negative metastatic breast cancer: experience from the patient perspective. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):929–940. doi: 10.1586/14737167.2014.949243.
   PubMed Web of Science ®Google Scholar
• Brufsky AM. Delaying chemotherapy in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Clin Med Insights Oncol. 2015;9:137–147. doi: 10.4137/CMO.S31586.
   PubMed Web of Science ®Google Scholar
• Finn RS, Rugo HS, Dieras VC, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL + LET) versus placebo plus letrozole (PBO + LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): analyses from PALOMA-2. American Society of Clinical Oncology. 2022.
   Google Scholar
• Goetz MP, Toi M, Huober J, et al. LBA15 MONARCH 3: interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2-advanced breast cancer (ABC). Ann Oncol. 2022;33:S1384. doi: 10.1016/j.annonc.2022.08.009.
   Web of Science ®Google Scholar